SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549

SCHEDULE 13G

Ur	nder the Securities Exchange Ad (Initial Filing)*	ct of 1934		
	SUCAMPO PHARMACEUTICALS, 1	INC.		
	(Name of Issuer)			
	CLASS A COMMON STOCK			
	(Title of Class of Securiti	ies)		
	864909106	,		
	December 31, 2007			
(Date of	Event which Requires Filing of	f this Statement)		
·	box to designate the rule purs	•		
is filed:	box to designate the rule purs	suant to witch this schedule		
[_] Rule 13d-1(b)				
[_] Rule 13d-1(c)				
[X] Rule 13d-1(d)				
person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page. The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act, but shall be subject to all other provisions of the Act (however, see the Notes).				
CUSIP No. 864909106		Page 2 of 5 Pages		
	RTING PERSONS: Astellas Pharma			
2 CHECK THE APP	PROPRIATE BOX IF A MEMBER OF A	GROUP (a) [_] (b) []		
3 SEC USE ONLY				
4 CITIZENSHIP (OR PLACE OF ORGANIZATION	Japan 		
NUMBER OF	5 SOLE VOTING POWER	1,253,750		
SHARES		-0-		
BENEFICIALLY OWNED BY EACH	7 SOLE DISPOSITIVE POWER	1,253,750		
	8 SHARED DISPOSITIVE POWER			

⁹ AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON:

1	0 CHECK BOX IF THE EXCLUDES CERTAIN	AGGREGATE AMOUNT IN ROW (9) SHARES	[_]
1	1 PERCENT OF CLASS BY AMOUNT IN ROW		8.1%
1	2 TYPE OF REPORTIN	G PERSON:	CO

Item 1(a) Name of Issuer:

Sucampo Pharmaceuticals, Inc.

Item 1(b) Address of Issuer's Principal Executive Offices:

4520 East West Highway, Third Floor Bethesda, Maryland 20814

Item 2(a) Name of Person Filing:

Astellas Pharma Inc.

Item 2(b) Address of Principal Business Office:

> 3-11, Nihonbashi-Honcho 2-chome Chuo-ku, Tokyo 103-8411 Japan

Item 2(c) Citizenship:

Japan

Item 2(d) Title of Class of Securities:

Class A Common Stock

Item 2(e) CUSIP Number:

864909106

If this statement is filed pursuant to ss.ss. 240.13d-1(b), or Item 3 240.13d-2(b) or (c), check whether the person filing is a:

Not applicable.

Item 4 Ownership.

> Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1.

- (a) Amount beneficially owned: 1,253,750 shares
- (b) Percent of class: 8.1%
- (c) Number of shares as to which the person has:
 - Sole power to vote or to direct the vote: 1,253,750 (i)

- (ii) Shared power to vote or to direct the vote: 0
 - (iii) Sole power to dispose or to direct the disposition of: 1,253,750
 - (iv) Shared power to dispose or to direct the disposition of: $\ensuremath{\text{0}}$
- Item 5 Ownership of Five Percent or Less of a Class.

Not applicable.

Item 6 Ownership of More than Five Percent on Behalf of Another Person.

Not applicable.

Item 7 Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.

Not applicable.

Item 8 Identification and Classification of Members of the Group.

Not applicable.

Not applicable.

Item 10 Certification:

Not applicable.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Date: February 12, 2008

ASTELLAS PHARMA INC.

/s/ Hirofumi Onosaka

By: Hirofumi Onosaka

Its: Senior Corporate Officer CFO & Chief Strategy Officer